Evaluation of population immunity against SARS-CoV-2 variants, EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4, using samples from two health demographic surveillance systems in Kenya
Authors:
- Doreen LuganoDLDoreen Lugano
- Makobu KimaniMKMakobu Kimani
- Antipa SigilaiASAntipa Sigilai
- John GitongaJGJohn Gitonga
- Angela KaraniAKAngela Karani
- Donald AkechDADonald Akech
- Boniface KariaBKBoniface Karia
- Abdhalah K. ZirabaAZAbdhalah K. Ziraba
- Angela MainaAMAngela Maina
- Arnold LambisiaALArnold Lambisia
- Donwilliams OmuoyoDODonwilliams Omuoyo
Preprint
Abstract
Increased immune evasion by emerging and highly mutated SARS-CoV-2 variants is a key challenge to the control of COVID-19. The majority of these mutations mainly target the spike protein, allowing the new variants to escape the immunity previously raised by vaccination and/or infection by earlier variants of SARS-CoV-2. In this study, we investigated the neutralizing capacity of antibodies against emerging variants of interest circulating between May 2023 and March 2024 using sera from representative samples of the Kenyan population. From our genomics data, we identified the most prevalent Kenyan and global variants and performed pseudoviruses neutralization assays with the most recent SARS-CoV-2 variants. Our data show that antibodies from individuals in the general population in Kenya were less effective against the recent prevalent SARS-CoV-2 omicron variants (i.e. EG.5.1, FY.4, BA.2.86, JN.1, and JN.1.4) compared to the ancestral wildtype strain. Although there was increased neutralization following multiple doses of vaccine, antibodies from >40% of the vaccinated individuals did not neutralize the omicron variants, suggesting that individuals were susceptible to infection by these variants.Keywords
This publication has 32 references indexed in Scilit:
- Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasionNature Communications, 2024
- Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variantsCell, 2024
- Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal modelScientific Reports, 2024
- Characterization of a SARS-CoV-2 EG.5.1 clinical isolate in vitro and in vivoCell Reports, 2023
- Effectiveness of monovalent and bivalent COVID-19 vaccinesThe Lancet Infectious Diseases, 2023
- Evolutionary characteristics of SARS-CoV-2 Omicron subvariants adapted to the hostSignal Transduction and Targeted Therapy, 2023
- Serum immunoglobulin G and mucosal immunoglobulin A antibodies from prepandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitroInternational Journal of Infectious Diseases, 2022
- SARS-CoV-2 variants, spike mutations and immune escapeNature Reviews Microbiology, 2021
- Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody DeficiencyJournal of Clinical Immunology, 2021
- COVID-19: Transmission, prevention, and potential therapeutic opportunitiesClinica Chimica Acta, 2020